BioScale, Inc. today announced that the company is changing its name to ProterixBio, Inc. The name change reflects a new strategic direction centered on high value clinical apps including diagnostics products and disease management services. ProterixBio’s initial focus is on pulmonary diseases such as COPD (chronic obstructive pulmonary disease), which affects more than 12 million Americans.
The company has made significant progress toward these new goals, including:
– Recruitment of a world-class scientific advisory board composed of experts in pulmonary and inflammatory diseases and diagnostics
– Establishment of a number of collaborations with leading institutions to gain access to high quality retrospective and prospective patient samples supporting development of a pipeline of complex diagnostic tests
– Rapid development of a growing number of validated, high quality pulmonary and inflammatory biomarker assays
– Plans for conversion of assay development facilities into GLP- and CLIA-ready labs
– Engagement with thought leaders and providers of digital health technologies and new health care delivery and disease management models
To advance this important mission, ProterixBio has assembled a Scientific Advisory Board consisting of leading international physician scientists and experienced industry leaders in the pulmonary and related disease space. In addition to Dr. Finn the other members of ProterixBio’s SAB are Drs. Paul Billings(formerly Chief Medical Officer of Life Technologies, Carlsbad, CA), Craig Gerard(Chief of Respiratory Diseases at Boston Children’s Hospital, Boston, MA),Robert Stockley (Professor of Medicine, University Hospital Birmingham, U.K.),Christian Weber (Professor and Director, Institute for Cardiovascular Prevention,Munich, Germany) and Wisia Wedzicha (Professor of Respiratory Medicine, Heart and Lung Institute, Imperial College, London, U.K.).
While ProterixBio is currently focused primarily on pulmonary diseases, the company’s unique platform and expertise are easily applied to other disease areas. In particular, other diagnostic opportunities are currently being explored in neurodegenerative and oncologic diseases.
